Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
about
Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and InflameAnimal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under DevelopmentMolecular Pathogenesis of NASHPPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in miceTissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα DeficiencyEthanol exposure depletes hepatic pigment epithelium-derived factor, a novel lipid regulator.Molecular pathways in non-alcoholic fatty liver disease.Arginase inhibition ameliorates hepatic metabolic abnormalities in obese mice.PPARs, Obesity, and InflammationReactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.RORα decreases oxidative stress through the induction of SOD2 and GPx1 expression and thereby protects against nonalcoholic steatohepatitis in mice.Recent advances in the development of farnesoid X receptor agonistsControlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet.Iron dextran increases hepatic oxidative stress and alters expression of genes related to lipid metabolism contributing to hyperlipidaemia in murine modelUpregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism.Effects of the interaction of diabetes and iron supplementation on hepatic and pancreatic tissues, oxidative stress markers, and liver peroxisome proliferator-activated receptor-α expression.A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.Modifying Choroidal Neovascularization Development with a Nutritional Supplement in MiceNonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitisSustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats.Health implications of high dietary omega-6 polyunsaturated Fatty acids.The Role of PPARs in Lung Fibrosis.NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr.Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.Dietary fiber prevents obesity-related liver lipotoxicity by modulating sterol-regulatory element binding protein pathway in C57BL/6J mice fed a high-fat/cholesterol dietThe Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.Role of Pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent modelMechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet.PKCδ as a regulator for TGFβ1-induced α-SMA production in a murine nonalcoholic steatohepatitis model.Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells.
P2860
Q26775571-371528DA-55D6-43A7-8270-B8E42D398616Q26781761-48E41CDF-4FAE-48A7-B0CC-4227E7EB2292Q28071265-CF02E563-E6E0-44A9-9823-43195E7D582BQ30241952-19C0B13B-4CB5-48DD-BFB1-F58E5CCA2718Q30513404-6D925D4B-2A0B-4C0A-92EB-B8144D1D4A4FQ33556288-DC7AD350-447B-4439-B90E-EA1EBCC6373EQ33631584-9CACFF87-057A-4660-B24B-B0EDDFAD5B99Q33708754-5E377D3D-74C1-4069-96F5-92E9EFB1B96AQ33890230-AF2AADB1-4073-4E82-9A7B-909DC46B02BCQ33946024-66E24EEF-8EEB-43B2-AB79-B6CE71F69341Q34003196-64435AED-52D4-42D4-814B-FEBFDAE9B0FFQ34009236-A5888F26-5CF4-4A23-AFAF-A28D6A50F645Q34401755-C4FF9B24-9C89-42F6-A610-D7A4D37673C7Q34431785-2E0F3178-1A61-427D-A75F-532FA1ADA19CQ34464043-D5169459-AABD-40F5-9CAE-4A44D0D851E4Q34464742-E4A57B30-E265-463F-AB20-69BE6C123513Q34997052-00A3B3F5-1F83-4EEF-8926-19416CBF5586Q35035662-ED7B5445-F2F8-4E61-9E0D-D77ACD28EAB7Q35037636-7947E98C-6230-49BC-84C2-0527BA0E5690Q35057717-253A8E1A-D928-44F1-9539-38931B824DC7Q35131341-9E393DDB-1B02-43BB-B680-5D2762A4ED7BQ35209655-D3FCE5DF-BD80-4DAC-A860-CD8419E0F3E7Q35222087-4D7D6CD7-7122-4BFE-8BC0-59F7B2040A91Q35679584-3ADAC695-8C6A-4BAE-8799-F2E00FF44A9FQ35685717-9A43AF7E-EB04-409D-BA01-6058C3855A77Q35753377-5E9392B2-C8F5-4EC1-8940-7F7AB6167767Q35761434-0D76560C-749C-48CE-AC5F-774AA52A6765Q35790318-033EEE01-E5AD-4317-9DCE-4C7F6A64368CQ35884061-29CFAA2C-3768-4038-8D6C-2ABB73F5B536Q35909254-078888EB-A9B7-43B3-A4B2-0DAE23BCF2A7Q35925362-248C9ABA-3427-455E-B820-F9E0F33369C8Q35931190-6038DA7D-082F-4BD9-A90E-4689FFF89DB6Q35946481-A0AC570E-A6A6-420B-BA0E-5EE12C5B0D70Q36168809-AA62F791-3094-4229-9FEA-674A66C5810FQ36221625-A714E4DF-6BF1-49E6-951C-CBA8984209F4Q36246806-EB51450F-15C8-4BD2-B949-65D6C11FAB05Q36492869-2C8945A3-E2FD-4926-BBC3-20FB2269690CQ36558384-F04C52AB-7AED-4CC0-B933-332E639EBF7AQ36618345-AC87C98D-75BE-4DE0-A664-7C8C0C845333Q36618918-4EA3E0CD-B4DF-475D-8039-BA295BD5049E
P2860
Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Administration of the potent P ...... s and steatohepatitis in mice.
@en
Administration of the potent P ...... s and steatohepatitis in mice.
@nl
type
label
Administration of the potent P ...... s and steatohepatitis in mice.
@en
Administration of the potent P ...... s and steatohepatitis in mice.
@nl
prefLabel
Administration of the potent P ...... s and steatohepatitis in mice.
@en
Administration of the potent P ...... s and steatohepatitis in mice.
@nl
P2093
P356
P1433
P1476
Administration of the potent P ...... s and steatohepatitis in mice.
@en
P2093
Geoff Farrell
Graham Robertson
Isabelle Leclercq
Pauline Hall
P304
P356
10.1002/HEP.20170
P407
P577
2004-05-01T00:00:00Z